Compare AJANTA PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA LUPIN AJANTA PHARMA/
LUPIN
 
P/E (TTM) x 22.5 47.5 47.3% View Chart
P/BV x 4.0 2.4 162.8% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 AJANTA PHARMA   LUPIN
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
LUPIN
Mar-19
AJANTA PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,422986 144.2%   
Low Rs898720 124.6%   
Sales per share (Unadj.) Rs233.5369.5 63.2%  
Earnings per share (Unadj.) Rs44.013.4 328.0%  
Cash flow per share (Unadj.) Rs52.237.4 139.5%  
Dividends per share (Unadj.) Rs9.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs255.1303.7 84.0%  
Shares outstanding (eoy) m88.02452.49 19.5%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x5.02.3 215.1%   
Avg P/E ratio x26.463.6 41.4%  
P/CF ratio (eoy) x22.222.8 97.4%  
Price / Book Value ratio x4.52.8 161.8%  
Dividend payout %20.50-   
Avg Mkt Cap Rs m102,081386,064 26.4%   
No. of employees `0006.817.7 38.5%   
Total wages/salary Rs m4,30731,513 13.7%   
Avg. sales/employee Rs Th3,022.69,453.8 32.0%   
Avg. wages/employee Rs Th633.41,782.0 35.5%   
Avg. net profit/employee Rs Th569.1343.0 165.9%   
INCOME DATA
Net Sales Rs m20,554167,182 12.3%  
Other income Rs m2113,640 5.8%   
Total revenues Rs m20,765170,822 12.2%   
Gross profit Rs m5,66428,822 19.7%  
Depreciation Rs m72110,850 6.6%   
Interest Rs m123,078 0.4%   
Profit before tax Rs m5,14318,534 27.7%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m1,2739,017 14.1%   
Profit after tax Rs m3,8706,066 63.8%  
Gross profit margin %27.617.2 159.9%  
Effective tax rate %24.848.7 50.9%   
Net profit margin %18.83.6 518.9%  
BALANCE SHEET DATA
Current assets Rs m11,812138,536 8.5%   
Current liabilities Rs m3,77661,299 6.2%   
Net working cap to sales %39.146.2 84.6%  
Current ratio x3.12.3 138.4%  
Inventory Days Days7784 92.4%  
Debtors Days Days82112 72.6%  
Net fixed assets Rs m14,398127,516 11.3%   
Share capital Rs m175905 19.4%   
"Free" reserves Rs m22,277136,517 16.3%   
Net worth Rs m22,452137,422 16.3%   
Long term debt Rs m766,417 0.0%   
Total assets Rs m26,962279,494 9.6%  
Interest coverage x444.37.0 6,328.8%   
Debt to equity ratio x00.5 0.1%  
Sales to assets ratio x0.80.6 127.4%   
Return on assets %14.43.3 440.0%  
Return on equity %17.24.4 390.5%  
Return on capital %23.08.9 257.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68259,414 18.0%   
Fx outflow Rs m2,10222,282 9.4%   
Net fx Rs m8,58037,132 23.1%   
CASH FLOW
From Operations Rs m3,74816,660 22.5%  
From Investments Rs m-2,228-32,825 6.8%  
From Financial Activity Rs m-1,4757,441 -19.8%  
Net Cashflow Rs m45-8,724 -0.5%  

Share Holding

Indian Promoters % 73.8 46.6 158.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 1.6 11.3 13.7%  
FIIs % 7.6 31.9 23.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.1 168.3%  
Shareholders   20,968 98,259 21.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - BIOCON COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS